About: Clinical Performance of SARS-CoV-2 Molecular Tests

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical Performance of SARS-CoV-2 Molecular Tests Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical Performance of SARS-CoV-2 Molecular Tests
Creator	Whittier, Susan Sobieszczyk, Magdalena Westblade, Lars Green, Daniel Boehme, Amelia Cushing, Melissa Liu, Dakai Rennert, Hanna Sepulveda, Jorge Zucker, Jason Craney, Arryn Velu, Priya
Source	Medline; PMC
abstract	Molecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the gold standard for diagnosis of coronavirus disease 2019 (COVID-19), but the clinical performance of these tests is still poorly understood, particularly with regard to disease course, patient-specific factors, and viral shedding. From 10 March to 1 May 2020, NewYork-Presbyterian laboratories performed 27,377 SARS-CoV-2 molecular assays from 22,338 patients. Repeat testing was performed for 3,432 patients, of which 2,413 had initial negative and 802 had initial positive results. Repeat-tested patients were more likely to have severe disease and low viral loads. The negative predictive value of the first-day result among repeat-tested patients was 81.3% The clinical sensitivity of SARS-CoV-2 molecular assays was estimated between 58% and 96%, depending on the unknown number of false-negative results in single-tested patients. Conversion to negative was unlikely to occur before 15 to 20 days after initial testing or 20 to 30 days after the onset of symptoms, with 50% conversion occurring at 28 days after initial testing. Conversion from first-day negative to positive results increased linearly with each day of testing, reaching 25% probability in 20 days. Sixty patients fluctuated between positive and negative results over several weeks, suggesting that caution is needed when single-test results are acted upon. In summary, our study provides estimates of the clinical performance of SARS-CoV-2 molecular assays and suggests time frames for appropriate repeat testing, namely, 15 to 20 days after a positive test and the same day or next 2 days after a negative test for patients with high suspicion for COVID-19.
has issue date	2020-07-23(xsd:dateTime)
bibo:doi	10.1128/jcm.00995-20
bibo:pmid	32513858
has license	no-cc
sha1sum (hex)	dea45ea0405500fa6e17dc224de20def4b10cf60
schema:url	https://doi.org/10.1128/jcm.00995-20
resource representing a document's title	Clinical Performance of SARS-CoV-2 Molecular Tests
has PubMed Central identifier	PMC7383556
has PubMed identifier	32513858
schema:publication	J Clin Microbiol
resource representing a document's body	covid:dea45ea0405500fa6e17dc224de20def4b10cf60#body_text
is schema:about of	named entity 'onset' named entity 'day' named entity 'patients' named entity 'high' named entity 'false-negative' named entity 'regard' named entity 'suspicion' named entity 'positive' named entity 'SUMMARY' named entity 'POSITIVE AND NEGATIVE' named entity 'TEST' covid:arg/dea45ea0405500fa6e17dc224de20def4b10cf60 named entity 'March' named entity 'negative' named entity 'initial' named entity 'coronavirus disease 2019' named entity 'The' named entity 'assays' named entity 'needed' named entity 'loads' named entity 'gold standard' named entity 'negative' named entity 'initial' named entity 'gold standard' named entity 'coronavirus disease 2019' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'asymptomatic' named entity 'RNA' named entity 'negative result' named entity 'emergency department' named entity '8 days' named entity 'SARS-CoV-2' named entity 'infection' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'negative result' named entity 'internal control' named entity 'Latino' named entity 'Caucasian race' named entity 'positive test' named entity 'clinical characteristics' named entity 'COVID-19' named entity 'intensive care unit' named entity 'false negatives' named entity 'viral load' named entity 'observational study' named entity 'PCR' named entity 'viscosity' named entity '28 days' named entity 'cumulative probability' named entity 'electronic medical record' named entity 'infection' named entity 'SARS-CoV-2' named entity 'RT-PCR' named entity 'Kaplan-Meier estimator' named entity 'SARS-CoV-2' named entity 'nosocomially' named entity 'SARS-CoV-2' named entity 'infection' named entity 'SARS-CoV-2' named entity 'sampling bias' named entity '10.5' named entity 'infection' named entity 'SARS-CoV-2' named entity 'initial testing' named entity 'New York City' named entity 'selection bias' named entity 'COVID-19 test' named entity 'COVID-19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software